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Edited by Hans EklundAbstract Dominant mutations in the ubiquitous enzyme glycyl-
tRNA synthetase (GlyRS), including S581L, lead to motor nerve
degeneration. We have determined crystal structures of wildtype
and S581L-mutant human GlyRS. The S581L mutation is
50 A˚ from the active site, and yet gives reduced aminoacylation
activity. The overall structures of wildtype and S581L-GlyRS,
including the active site, are very similar. However, residues
567–575 of the anticodon-binding domain shift position and in
turn could indirectly aﬀect glycine binding via the tRNA or alter-
natively inhibit conformational changes. Reduced enzyme
activity may underlie neuronal degeneration, although a domi-
nant-negative eﬀect is more likely in this autosomal dominant
disorder.
 2007 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Aminoacyl-tRNA synthetases (ARS) are a phylogenetically
ancient family of enzymes which ensure the ﬁdelity of transla-
tion from genetic code to amino acid code by coupling amino
acids with their cognate tRNA. GlyRS consists principally of a
catalytic core and an anticodon-binding domain. Whilst the
prokaryotic and yeast enzymes exist as heterotetramers, higher
eukaryotic GlyRS are homodimers [1]. The anticodon-binding
domains diﬀer between early prokaryotes and eukaryotes but
the catalytic core has a higher degree of homology. Thus the
anticodon-binding domain appears to be an evolutionary
adaptation to the protein to aid in cognate tRNA recogni-
tion[2]. Acquisition of new structural motifs may have also
conferred the non-canonical functions observed in many
tRNA synthetases [3].Abbreviations: GlyRS, glycyl-tRNA synthetase; Wt, wildtype; Hs,
Homo sapiens; tt, Thermus thermophilus
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doi:10.1016/j.febslet.2007.05.046GARS, the gene encoding GlyRS, was ﬁrst implicated in
neurodegeneration through linkage and positional cloning
studies in families segregating either Distal Spinal Muscular
Atrophy type V (dSMAV) or Charcot–Marie–Tooth Type
2D (CMT-2D)[4–8]. Both disorders are characterised by ado-
lescent onset slowly progressive muscle weakness, often prefer-
entially involving the distal muscles of the upper limb.
Missense mutations causing dSMAV/CMT2D have been
found to be dispersed throughout the coding regions of GARS
without an apparent pattern relating to the known functional
domains of the protein [5,9–11]. We have recently identiﬁed
two mutations in the anticodon-binding domain, S581L and
G598A [12]. S581L and G598A mutations are interesting since
the patients carrying them develop disease onset at younger
ages than previously described for other GlyRS mutations.
Given the ubiquitous expression and basic biological func-
tion of GlyRS, it is intriguing that mutations in such pivotal
proteins can speciﬁcally cause neuronal degeneration. A num-
ber of recent additional ﬁndings indicate that ARS may have a
broader role in neurodegeneration. Mutations in tyrosyl-
tRNA synthetase (TyrRS) were identiﬁed as a cause of an
intermediate form of CMT [13] and a mutation in the editing
domain of Alanine tRNA synthetase (AlaRS) causes severe
cerebellar degeneration in a mouse model [14]. In order to bet-
ter understand the role of GlyRS in motor neuron survival, we
have solved crystal structures and determined steady-state
kinetic parameters for wildtype and S581L proteins.2. Materials and methods
2.1. Expression and puriﬁcation of hsGlyRS
GARS cDNA in a pCMV vector was obtained from Origene (US).
Human GlyRS has two translation start sites. We cloned the shorter
cytoplasmic variant and incorporated a PCR-introduced C-terminal
His-tag into the expression vector pET22b giving the GARS-pET22b
construct. The S581L mutation was introduced with appropriate syn-
thetic oligonucleotide primers using standard procedures.
Transformed Escherichia coli, BL21 (DE3) strain, were grown in a
starter culture of LB medium containing 50 lg/mL ampicillin over-
night at 37 C. After dilution to 1:500 with fresh medium, cells were
grown at 37 C until an OD600 of 0.8 was reached and induced with
0.1 mM IPTG. Following overnight incubation at 18 C, cells were
harvested by centrifugation at 4000 · g for 20 min. Cell pellets wereblished by Elsevier B.V. All rights reserved.
Table 1
Data collection and reﬁnement statistics
Wt-hsGlyRS S581L-hsGlyRS
Data collection
Space group P43212 P43212
Cell dimensions
a, b, c (A˚) 92.0, 92.0, 247.7 92.5, 92.5, 246.9







Resolution (A˚) 30–3.1 30–2.8
Reﬂections used 19358 27257
Rwork/Rfree
b 0.228/0.280 0.228/0.282
Number of atoms: protein
and water
4242 4269
Rms deviation bonds (A˚) 0.008 0.006
Rms deviation angles () 1.4 1.3
Mean B-factor 57.8 50.1
aRmerge ¼
P jI  hIij=PhIi.
bR factor ¼P jF O  fCj=
P
F O.
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mercaptoethanol, pH 8.0. Following sonication on ice, lysed cells were
centrifuged at 34000 · g for 20 min at 4 C, hsGlyRS was puriﬁed
from the supernatant on BD Talon Nickel-NTA resin according to
manufacturer’s instructions and eluted with 500 mM imidazole. Gel ﬁl-
tration chromatography used a 30 ml Superose-12 column equilibrated
with 60 mM TRIS, pH 7.5, 10 mMMgCl2, 100 mM KCl. Liquid chro-
matography–mass spectrometry was used to assess molecular weights
of wt and mutant hsGlyRS.
2.2. Crystallisation and structure determination
Both wildtype and mutant form of hsGlyRS were screened by sitting
drop vapour diﬀusion nanocrystallization procedures at 20 C using
standard Oxford Protein Production Facility protocols [15]. S581L-
hsGlyRS crystallised readily under many conditions. Crystals diﬀract-
ing to 2.8 A˚ resolution grew for S581L-hsGlyRS in 20% PEG3350,
0.2 M Na2SO4, 0.1 M bis-TrisPropane pH 6.5. Crystals of wt-hsGlyRS
diﬀracting to 3.1 A˚ resolution grew in 20% PEG3350, 0.2 M sodium
bromide, 0.1 M bis-TrisPropane pH 8.5.
X-ray data collected at the ESRF, Grenoble, France, were processed
with Denzo and Scalepack [16], model rebuilding with O [17] and
reﬁnement with CNS [18]. The wt-hsGlyRS structure was determined
by molecular replacement using Thermus themophilus GlyRS (PDB:
1ati); 35% sequence identity with hsGlyRS [19]. There was one enzyme
molecule per asymmetric unit in space group P43212. Data collection
and reﬁnement statistics are summarised in Table 1. Residues 1–63,
433–511, 674–685 had only limited electron density and thus appeared
largely disordered. Electrostatic surface potentials were calculated by
APBS. Figures were created using Pymol.
2.3. Enzyme kinetics
Aminoacylation assays were performed with 60 mM TRIS,
pH 7.5, 30 mM KCl, 10 mM MgCl2, 5 mM ATP, 0.1 mg/mL BSA,
1 mM b-mercaptoethanol, [3H] or [14C] glycine and in vitro transcribed
tRNAgly(GCC) using standard Promega kits. Reactions in 10 ll aliquots
at 37 C were initiated by enzyme addition. Initial reaction rates, for
diﬀering concentrations of glycine and tRNA were determined in trip-
licate experiments. Kinetic parameters were determined using linear
plots of [s]/v against [s].3. Results
3.1. Structural architecture
GARS has two translation start sites [20], encoding mito-
chondrial and cytoplasmic forms; we have used the shorter685 residue cytoplasmic hsGlyRS form. Mass spectrometry
and analytical gel-ﬁltration indicate hsGlyRS is a homodimer
of 155 kDa (data not shown). Overall wt-hsGlyRS and
S581L-hsGlyRS had similar conformations, reﬂected by a
Ca RMSD of 0.44 A˚, although residues 567–575 showed a
larger RMSD of 1.2 A˚, which may be of functional signiﬁ-
cance (see Section 3.5). This displaced 567–575 loop does
not form part of any crystal contacts and indeed both wild-
type and mutant GlyRS crystals are essentially isomorphous.
Hence, it is unlikely that the loop displacement is due to a
crystal packing eﬀect.
GlyRS has a modular architecture consisting of a catalytic
core, a C-terminal anticodon-binding domain together with
other appended motifs (Fig. 1a and b). The N-terminal resi-
dues, 17–44, are found in synthetases which form a multi-syn-
thetase complex, although GlyRS has yet to be shown to be
directly involved in such a complex [21]. Residues 98–130, a
conserved region denoted as Motif1 have been suggested to
be involved in active site formation and enzyme dimerisation
[19].
The catalytic core has seven antiparallel beta-strands typical
of Class II tRNA synthetases. Two highly conserved motifs
present in all GlyRS species, Motifs 2 and 3, contain ATP-
binding residues [22]. Motifs 1 and 2 are separated by an
insertion domain, Insertion Domain 1, which in ttGlyRS
was predicted to interact with the minor groove of tRNA
[19]. In ttGlyRS this domain was largely disordered but is well
visualised in hsGlyRS. Two further insertions are present in
hsGly- RS but not in ttGlyRS: Insertion Domain 2, residues
304–349, is appended after Motif 2 and consists of two short
helices and beta-strands. The function of Insertion Domain 2
is diﬃcult to infer since it lies away from the dimer interface
and tRNA-binding site. Insertion Domain 3, residues 433–
510, is present after Motif3 but had poor electron density
and thus largely disordered. The anticodon-binding domain
is a ﬁve-stranded mixed parallel and anti-parallel beta-sheet
surrounded by three alpha helices. This domain distinguishes
hsGlyRS as a member of the group of Class IIa synthetase
[23].
DALI structural similarity searches showed the expected sig-
niﬁcant structural homology of hsGlyRS with other Class IIa
tRNA synthetases. Additionally, human GlyRS has remark-
able structural similarity to mammalian mitochondrial DNA
polymerase gamma beta subunit, Polc–b (1g5 H, RMSD
2.6 A˚, 67% equivalent Cas), despite an amino-acid sequence
identity of only 18%, Fig. 1c. Polc–b forms a homodimer
but is unlikely to have tRNA synthetase activity since key
residues at the active site and on the anticodon-binding do-
main are not conserved [24]. Whilst there is minimal amino-
acid sequence identity at the dimer interface, the secondary
structure is highly homologous.3.2. Dimer interface
HsGlyRS exists and functions as a homodimer with mono-
mers related by a twofold rotation axis, (Fig. 1d). The dimer-
isation surface is extensive (5393 A˚2), comprising 10.5% of the
accessible surface area with 79 residues from each monomer di-
rectly contributing to the interface. Two large interface patches
are formed by residues 76–137 and 220–290, respectively.
These domains create two protruding loops which ﬁt into
pockets of the partnering monomer thereby orientating the
Fig. 1. Human GlyRS structure: (a) ribbon diagrams showing modular architecture of hsGlyRS. Purple, Motif 1; red, Motifs 2 and 3 of catalytic
domain containing active site; blue, anticodon-binding domain; green, Insertion Domain 1; yellow, Insertion Domain 2. (b) hsGlyRS rotated through
90 to show binding pocket. (c) Superposition of mammalian polymerase gamma accessory subunit, PDB: 1g5H (blue) onto hsGlyRS (green). (d)
hsGlyRS homodimer, subunits are coloured blue and purple, with modelled tRNA docked onto surface. (e) Disease causing hsGlyRS mutations
highlighted in red on protein dimer.
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dimer formation in hsGlyRS function is highlighted by the de-
gree of conservation seen in residues directly involved at the
interface. Dimerisation may also be critical for correct active
site formation since Motif 1 of one monomer is in direct con-
tact with Motif 2 of its partner.3.3. tRNA-binding site
An alignment of hsGlyRS with the threonyl-tRNA in com-
plex with its cognate tRNA (PDB: 1QF6)[25], showed the
tRNA lies in a crevice at the interface between the subunits
of the hsGlyRS homodimer, (Fig. 1d). Analysis of the electro-
static surface potential reveals a positively charged region,
2962 M.Z. Cader et al. / FEBS Letters 581 (2007) 2959–2964which includes the undersurface of Insertion Domain 1,
around the negatively charged active site. This likely facilitates
binding of the negatively charged tRNA by guiding the accep-
tor arm into the active site. The modelled tRNA has some
steric clashes with the Insertion Domain 1 and thus conforma-
tional changes on tRNA binding are likely. Whilst Insertion
Domain 3 was largely disordered in our structures, some
observed electron density overlies the modelled tRNA. The
domain may become ordered upon tRNA binding and interact
with it.
3.4. Active site
The active site is a highly negatively charged pocket as has
been described for ttGlyRS [26] with key ATP, glycine and
magnesium-binding residues all conserved in human GlyRS
(data not shown). Comparison of S581L- and wt-hsGlyRS
shows the active site residues are in similar conformations
apart from small shifts in the orientation of R288 and D392,
which bind adenine and magnesium, respectively.
3.5. Mapping mutations causing dSMAV/CMT2D and
structural eﬀects of S581L
To date, there are nine identiﬁed missense mutations in
hsGlyRS that cause clinical symptoms of dSMAV or CMT-
2D (Fig. 1e). E71G, I280F and G598A appear to be directly
located at the tRNA interface. D500N is on an insertion do-
main which is also likely to directly interact with the tRNA.
L129P, G240R, H418R and I280F are on the dimer interface
with the ﬁrst three of these residues completely buried upon
dimerisation. G526R is located at the active site.
S581L lies on the anticodon-binding domain but opposite to
the tRNA-binding surface and the electron density in the re-
gion of S581L is shown in Fig. 2a. The S581L mutation results
in the loss of contact with the following atoms: CB and CG of
L580, N of A583 and CB of T585. Additional contacts are
made with following atoms: CB and CG1 of V564, CG1 of
V577, N of L580 and CG of H591. The mutation therefore
causes a small shift in the adjoining beta-turn, residues 567–
575 (Fig. 2b). This loop is displaced with a Ca RMSD of
1.24 A˚ compared to an RMSD of 0.44 A˚ for the structures
overall. As indicated in Fig. 2b, the loop may interact withFig. 2. (a) 2fo–fc map in the region of the S581L mutation. Electron dens
(green) and wt-hsGlyRS (grey) in region of S581L mutation showing tRN
hsGlyRS.tRNA and indeed the anticodon bases C34, G35 and U36 of
the modelled tRNA are in close proximity.
3.6. Aminoacylation activity of wildtype and S581L-hsGlyRS
Steady-state enzyme kinetic parameters were determined for
wildtype and S581L-hsGlyRS using radiolabelled glycine and
the in vitro transcript, tRNAgly(GCC). Wildtype enzyme had:
kcat, 0.31 ± 0.02 s
1; tRNAgly(GCC) Km, 1.3 ± 0.5 lM; and gly-
cine Km, 15.2 ± 5.5 lM. S581L-hsGlyRS had reduced activity:
kcat, 0.09 ± 0.01 s
1, tRNAgly(GCC) Km, 0.7 ± 0.2 lM and gly-
cine Km, 59.1 ± 13.5 lM. As noted above there are minimal
shifts, between S581L-mutant and wildtype in the substrate
binding residues responsible for coordinating glycine. A simple
steric change in the glycine site is therefore not apparent to
explain the higher Km (59.1 lM versus 15.2 lM). Although
as Km is a combination of kinetic constants this may not nec-
essarily equate to a value for Kd. Thus, a more complex mech-
anism for the lower aminoacylation activity seems likely and is
discussed in more detail below.4. Discussion
This study provides the ﬁrst report of crystal structures of a
full-length human ARS and lays the foundations for insights
into hsGlyRS structure–function relationships. Diﬀraction
data have previously been reported for hsGlyRS but a struc-
ture has not been published [27]. Nine diﬀerent missense muta-
tions causing dSMAV or CMT2D have been identiﬁed and all
lie within highly conserved regions. Despite 35% sequence
identity between ttGlyRS and hsGlyRS, four of the mutated
residues are not present in ttGlyRS. The S581L mutation is lo-
cated on an alpha-helix in the anticodon-binding domain and
induces a local conformation change. The adjoining proximal
beta-turn of residues 567–575, which is in a position to interact
with the tRNA anticodon, is displaced away from the tRNA in
S581L-hsGlyRS compared to wildtype.
Aside from this region, the overall structures of wildtype and
S581L-hsGlyRS are highly similar. It is interesting therefore
that the S581L mutation showed a marked reduction in cata-
lytic activity despite its location, >50 A˚ from the active site.ity is contoured at sigma = 1.2. (b) Superposition of S581L-hsGlyRS
A–anticodon interface. Arrows indicated displaced loop of S581L-
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and S581L-hsGlyRS, e.g. the ATP and Mg2+ binding residues
R288 and D392 are small and do not appear to be signiﬁcant.
However, although distally positioned residues have been pre-
viously shown to cause weaker inhibitor binding in HIV re-
verse transcriptase drug resistant mutants [28] and tighter
binding in antibody aﬃnity maturation [29], conformational
transmission from S581L-hsGlyRS through the protein to
the active site is not apparent.
It seems more likely that the S581L mutation may exert its
deleterious eﬀects via tRNA as there is a shift in position of
nearby residues. The tRNA may then indirectly aﬀect glycine
binding and give rise to non-optimal steady-state kinetic
parameters. Alternatively, S581L may cause interference with
conformational changes which normally would allow relative
movements of diﬀerent enzyme domains during the catalytic
cycle. In this regard, crystal structures of two other Class IIa
synthetases in complex with their cognate tRNA would seem
to indicate ligand-induced conformational changes. Hence,
threonyl-tRNA synthetase has tRNA bound at the anticodon
stem and the acceptor arm positioned within the active site
[25]. The tRNA acceptor arm in the prolyl-tRNA synthetase
complex, however, does not enter the active site and the
authors proposed a lever arm hinge eﬀect to bring the tRNA
into position perhaps mediated through prolyl-adenylate bind-
ing [30]. Interestingly, thermodynamic studies in Bombyx mori
GlyRS found large binding energy changes consistent with
conformation change upon binding of glycyl-adenylate [31].
Evidence from pre-steady-state enzyme kinetic studies suggests
long range communication eﬀects in glutaminyl-tRNA synthe-
tase. Mutation of U35 of tRNAgln aﬀecting tRNA-synthetase
interactions, 40 A˚ away from the active site, leads to a signiﬁ-
cant reduction in kchem and Kd for glutamine [32].
Several of the other hsGlyRS mutations are proximal to the
dimer interface and may disrupt dimer formation, hence caus-
ing loss of activity as the hsGlyRS monomer is inactive. The
importance of dimerization is apparent from the large contact
area, the high degree of conservation of interface residues and
involvement of both subunits in creating the tRNA-crevice.
Previous studies in yeast GlyRS have shown that dimers and
monomers are in equilibrium, whilst only dimers have signiﬁ-
cant in vitro activity [33]. Interestingly, the nmf259 mouse
has a P278K/Y mutation in mouse GlyRS leading to severe
degeneration of both motor and sensory nerves [34]. P278 cor-
responds to hsGlyRS P234 which lies on the dimer interface
making contact with ﬁve other residues including I280 which
can be mutated in human disease.
Mitochondrial and cytoplasmic hsGlyRS are encoded by the
same gene. The structural similarity with mitochondrial Polc–
b is therefore interesting, especially since mutations in human
Polc–b can cause neurological phenotypes such as external
ophthalmoplegia and ataxic neuropathy. Polc–b exists as a
homodimer and it is possible that mutant hsGlyRS sequesters
Polc subunits by acting as an aberrant binding partner. There
is considerable structural homology at the interface and
furthermore heterodimer formation has been demonstrated
between yeast GlyRS and ValRS [33] providing a precedent
for such interactions.
We have determined crystal structures for wildtype hsGlyRS
and the S581L-mutant that gives rise to motor nerve degener-
ation and shown a reduction in enzyme activity for the mutant
enzyme. Reduced activity may underlie disease pathogenesisalthough as a dominant disorder the normal allele would be
expected to provide a signiﬁcant reserve. Therefore, a domi-
nant-negative mechanism (possibly by aberrant dimer forma-
tion), misacylation or a non-canonical function is more likely
to underpin neuronal degeneration and this needs to be
explored further.
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